Darling Ingredients Earnings Call Transcripts
Fiscal Year 2026
-
Leadership highlighted accelerated momentum from RVO clarity, strong protein and fat markets, and a shift to cash generation. Collagen and peptide innovations are set to double food segment EBITDA in 3–5 years, while capital allocation will prioritize debt reduction, buybacks, and organic growth.
-
A global platform has been built through acquisitions and operational improvements, positioning for accelerated returns and strong cash generation. Renewable fuels and collagen are key growth drivers, with robust demand, margin expansion, and new product innovation. Debt reduction and disciplined capital allocation support future shareholder value.
-
The meeting confirmed a quorum, elected all director nominees, ratified KPMG as auditor, and approved both executive compensation and the 2026 Omnibus Incentive Plan. No shareholder proposals or questions were presented.
-
First quarter 2026 saw a dramatic earnings turnaround, with EBITDA more than doubling year-over-year and margin expansion across all segments. Regulatory clarity and strong demand in renewables and collagen drove results, while management remains focused on debt reduction and operational excellence.
-
The company has evolved into the world’s largest animal byproducts repurposer, leveraging vertical integration and a global footprint to drive growth in food, feed, and renewable energy. Recent policy developments are expected to boost margins, while new specialty collagen products offer significant upside. Focus remains on debt reduction and capitalizing on unique industry positioning.
Fiscal Year 2025
-
Q4 and FY2025 saw strong EBITDA and margin growth, driven by operational excellence and robust demand across segments. Portfolio optimization, debt reduction, and strategic acquisitions position the business for continued momentum, with 2026 outlook dependent on policy clarity.
-
Management expects imminent RVO policy clarity, with bullish renewable fuel mandates and improving margins for 2026. Collagen and peptide businesses are expanding, with a major JV and potential IPO by 2027. Focus remains on deleveraging, organic growth, and optimizing feed and food segments.
-
Core ingredients business achieved its best results in 18 months, with strong feed and food segment performance and improved margins. Renewables faced headwinds from policy delays and unusual LIFO/LCM losses, but Q4 outlook is optimistic, especially for DGD as policy clarity improves.
-
Q2 saw improved gross margins and stable sales, but EBITDA and net income declined year-over-year. Guidance anticipates sequential improvement, with rising fat prices and policy clarity expected to drive stronger results in 2025 and 2026.
-
Legislative support and higher RVO targets are set to boost margins and feedstock demand, while the business advances in SAF and specialty food ingredients. The Nextida JV is positioned for strong growth, and guidance is maintained with expectations for improved performance in the second half.
-
A new joint venture will combine two leading collagen and gelatin businesses, creating a global platform with $1.5 billion in annual revenue and high margins. The deal requires no cash investment, offers significant growth potential, and positions the entity for future monetization opportunities.
-
Core business delivered strong Q1 performance with improved margins and cash flow, despite biofuel market headwinds and DGD challenges. Full-year EBITDA guidance of $1.25–$1.3 billion was reaffirmed, with deleveraging and innovation in collagen products highlighted.
-
The renewable diesel market is undergoing rationalization due to oversupply and regulatory changes, with efficient producers poised to benefit as supply shifts domestic and demand grows. Sustainable aviation fuel operations are running at capacity, with strong sales and expansion potential. Regulatory and policy support remains robust, with further clarity expected later in the year.
-
The company has evolved into a global leader in animal byproduct processing, renewable fuels, and health-focused collagen products. Regulatory support and market demand for SAF and renewable diesel remain strong, while financial discipline and innovation position the business for long-term growth.
Fiscal Year 2024
-
Reported a strong Q4 and FY 2024 with improved margins, significant debt reduction, and robust cash flow from joint ventures. 2025 guidance calls for higher Adjusted EBITDA, continued deleveraging, and growth in SAF and renewable products, supported by favorable regulatory changes.
-
Uncertainty remains around 45Z credits and biofuel policy, but global mandates and supply chain shifts are expected to support margins. Feedstock markets are tightening, SAF operations are ramping up with strong margins, and the collagen business is expanding with new health-focused products.
-
Q3 2024 saw lower earnings and sales amid tough markets, but strong cash flow enabled debt reduction and continued investment. 2025 guidance is optimistic, with regulatory clarity, margin improvement, and new product launches expected to drive record earnings.
-
Q2 2024 saw improved core margins, debt reduction, and a $77.1M DGD dividend, but net income and sales declined year-over-year. Management reaffirmed $1.3–$1.4B adjusted EBITDA guidance, expecting stronger H2 performance as fat prices rise and operational initiatives take effect.